Synvista Therapeutics, Inc.

OTCPK:SYNI Stock Report

Market Cap: US$258.0

Synvista Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure17.8yrs

Recent management updates

No updates

Recent updates

No updates


CEO

Synvista Therapeutics has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Mary Tanner
Independent Director18.3yrsUS$89.14kno data
Bertram Pitt
Medical & Clinical Advisorno datano datano data
Noah Berkowitz
Director18.3yrsUS$445.08kno data
John Bedard
Independent Director17.2yrsUS$70.02kno data
Michael Zile
Medical & Clinical Advisorno datano datano data
William Little
Medical & Clinical Advisorno datano datano data
Dalane Kitzman
Medical & Clinical Advisorno datano datano data
Scott D. Solomon
Medical & Clinical Advisorno datano datano data
David Greenblatt
Medical & Clinical Advisorno datano datano data
William Federiciz
Director16.1yrsno datano data

17.8yrs

Average Tenure

71yo

Average Age

Experienced Board: SYNI's board of directors are seasoned and experienced ( 17.8 years average tenure).